

A Discussion of Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESIA Trials

Hosted by Jason T. Jacobson, MD, FHRS



Article Information:

Article for Discussion: <u>Direct Oral Anticoagulants for Stroke Prevention in Patients</u>
<u>With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials</u>

Authors: William F. McIntyre, Alexander P. Benz, Nina Becher, Jeffrey S. Healey, Christopher B. Granger, Lena Rivard, A. John Camm, Andreas Goette, Antonia Zapf, Marco Alings, Stuart J. Connolly, Paulus Kirchhof and Renato D. Lopes

Journal: Circulation



Today's Host



Jason T. Jacobson, MD, FHRS
Westchester Medical Center-New York
Medical College



Today's Contributors:



Christian Thomas Ruff, MD Brigham and Women's Hospital



William H. Sauer, MD, FHRS Brigham and Women's Hospital



Disclosures:

Christian Thomas Ruff, MD

- Honoraria/Speaking/Consulting: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals
- Research: Daiichi, MedImmune

Jason T. Jacobson, MD, FHRS

- Honoraria/Speaking/Consulting: American College of Cardiology, Zoll Medical Corporation
- Research: Abbott, Phillips
- Stock, Privately Held: Atlas 5D

William H. Sauer, MD, FHRS

- Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific
- Research: Medtronic





Thank you!